264 related articles for article (PubMed ID: 27021967)
1. Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study.
Molina L; Recinos B; Paz B; Rovelo M; Elias Rodriguez FE; Calderón J; Arellano A; Pomata S; Rey MV; Perez-Lloret S
Clin Drug Investig; 2016 Jun; 36(6):491-7. PubMed ID: 27021967
[TBL] [Abstract][Full Text] [Related]
2. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
[TBL] [Abstract][Full Text] [Related]
3. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.
Katila H; Mezhebovsky I; Mulroy A; Berggren L; Eriksson H; Earley W; Datto C
Am J Geriatr Psychiatry; 2013 Aug; 21(8):769-84. PubMed ID: 23567397
[TBL] [Abstract][Full Text] [Related]
5. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
Bauer M; Thase ME; Liu S; Earley W; Eriksson H
J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
[TBL] [Abstract][Full Text] [Related]
6. Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression.
Murasaki M; Koyama T; Kanba S; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
Psychopharmacology (Berl); 2018 Oct; 235(10):2859-2869. PubMed ID: 30069587
[TBL] [Abstract][Full Text] [Related]
7. Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression.
Kanba S; Murasaki M; Koyama T; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
BMC Psychiatry; 2019 Jun; 19(1):198. PubMed ID: 31242884
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial.
Li H; Gu N; Zhang H; Wang G; Tan Q; Yang F; Ning Y; Zhang H; Lu Z; Xu X; Shi J; Gao C; Li L; Zhang K; Tian H; Wang X; Li K; Li H; Xu Y; Xie S; Yu X
Psychopharmacology (Berl); 2016 Apr; 233(7):1289-97. PubMed ID: 26911380
[TBL] [Abstract][Full Text] [Related]
9. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population.
Pan PY; Lee MS; Yeh CB
BMC Psychiatry; 2015 Jan; 15():1. PubMed ID: 25609320
[TBL] [Abstract][Full Text] [Related]
11. Effect of quetiapine XR on depressive symptoms and sleep quality compared with lithium in patients with bipolar depression.
Kim SJ; Lee YJ; Lee YJ; Cho SJ
J Affect Disord; 2014 Mar; 157():33-40. PubMed ID: 24581825
[TBL] [Abstract][Full Text] [Related]
12. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia.
Ganesan S; Agambaram V; Randeree F; Eggens I; Huizar K; Meulien D;
Curr Med Res Opin; 2008 Jan; 24(1):21-32. PubMed ID: 18021496
[TBL] [Abstract][Full Text] [Related]
13. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study.
Riesenberg RA; Baldytcheva I; Datto C
Clin Ther; 2012 Nov; 34(11):2202-11. PubMed ID: 23059166
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial.
Garriga M; Solé E; González-Pinto A; Selva-Vera G; Arranz B; Amann BL; Saiz-Ruiz J; Pérez-Blanco J; Vieta E
Eur Neuropsychopharmacol; 2017 Oct; 27(10):959-969. PubMed ID: 28882405
[TBL] [Abstract][Full Text] [Related]
15. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
Meyer JM; Mao Y; Pikalov A; Cucchiaro J; Loebel A
Int Clin Psychopharmacol; 2015 Nov; 30(6):342-50. PubMed ID: 26196189
[TBL] [Abstract][Full Text] [Related]
16. Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder.
Locklear JC; Svedsäter H; Datto C; Endicott J
J Affect Disord; 2013 Jul; 149(1-3):189-95. PubMed ID: 23639212
[TBL] [Abstract][Full Text] [Related]
17. A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use.
Gao K; Ganocy SJ; Conroy C; Brownrigg B; Serrano MB; Calabrese JR
Psychopharmacology (Berl); 2017 Aug; 234(15):2233-2244. PubMed ID: 28536866
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
Liebowitz M; Lam RW; Lepola U; Datto C; Sweitzer D; Eriksson H
Depress Anxiety; 2010 Oct; 27(10):964-76. PubMed ID: 20734365
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression.
Suppes T; Datto C; Minkwitz M; Nordenhem A; Walker C; Darko D
J Affect Disord; 2010 Feb; 121(1-2):106-15. PubMed ID: 19903574
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.
Wang Z; Kemp DE; Chan PK; Fang Y; Ganocy SJ; Calabrese JR; Gao K
Int J Neuropsychopharmacol; 2011 Feb; 14(1):131-42. PubMed ID: 20875219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
